Wang Minghao, Hu Ying, Hou Lingmi, Pan Qinwen, Tang Peng, Jiang Jun
Breast Disease Center, Southwest Hospital, Army Medical University, Chongqing 400038, China.
Department of Thyroid and Breast Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China.
Gland Surg. 2019 Dec;8(6):758-765. doi: 10.21037/gs.2019.12.08.
In recent years, traditional Chinese medicine (TCM) has been developing rapidly in cancer treatment. Huaier is a widely used fungus by TCM to treat different kinds of cancers. Its good efficacy in prevention of tumor recurrence and metastasis has been proven by a large number of clinical studies. In order to further investigate the efficacy and safety of Huaier granules in post-surgical therapy for stage I-III triple-negative breast cancer (TNBC) patients, we performed a case-control clinical study to observe its effects on the post-surgical safety and survival rates of these patients.
Two hundred and one TNBC patients underwent modified radical mastectomy were selected, they were admitted to our hospital between October 2010 to September 2014. The patients were randomly allocated to the experimental group (101 cases) or the control group (100 cases). Patients in the experimental group were treated with Huaier granules, by orally taking 20 g each time with 3 times a day. Medication was started during chemotherapy or at the time in 6 or 18 months after it. The control group did not receive any TCM preparations during this process. The disease-free survival (DFS) and overall survival (OS) were measured as the main outcome.
The median follow-up time was 46 months. For the 100 patients in control group, 5-year DFS and OS was 82% and 86% respectively, while 87.1% and 90.1% for the 101 patients in the experimental group. The difference was not statistically significant. However, stage III patients in the control group showed a 5-year DFS of 53.8% and OS of 65.4%, which were significantly lower than that of stage III patients in the experimental group as 81.3% and 87.5%. In the experimental group, 10 patients with 6-month medication showed disease progression, whereas only 3 patients with 18-month medication showed disease progression. This difference was statistically significant as well.
Huaier granules could play an important role in post-surgical adjuvant therapy of TNBC patients, specially by effectively increasing the DFS and OS of breast cancer patients at middle to advanced stage.
近年来,中医在癌症治疗领域发展迅速。槐耳是中医广泛用于治疗各类癌症的一种真菌。大量临床研究已证实其在预防肿瘤复发和转移方面具有良好疗效。为进一步探究槐耳颗粒对Ⅰ - Ⅲ期三阴性乳腺癌(TNBC)患者术后治疗的疗效及安全性,我们开展了一项病例对照临床研究,以观察其对这些患者术后安全性及生存率的影响。
选取2010年10月至2014年9月期间在我院接受改良根治性乳房切除术的201例TNBC患者。将患者随机分为实验组(101例)和对照组(100例)。实验组患者服用槐耳颗粒,每次口服20克,每日3次。在化疗期间或化疗后6个月或18个月开始用药。在此过程中,对照组未接受任何中药制剂。以无病生存期(DFS)和总生存期(OS)作为主要观察指标。
中位随访时间为46个月。对照组100例患者5年DFS和OS分别为82%和86%,而实验组101例患者分别为87.1%和90.1%。差异无统计学意义。然而,对照组Ⅲ期患者5年DFS为53.8%,OS为65.4%,显著低于实验组Ⅲ期患者的81.3%和87.5%。在实验组中,服药6个月的10例患者出现疾病进展,而服药18个月的仅3例患者出现疾病进展。这一差异也具有统计学意义。
槐耳颗粒在TNBC患者术后辅助治疗中可发挥重要作用特别是能有效提高中晚期乳腺癌患者的DFS和OS。